TY - JOUR AU - Donnem, Tom AU - Bremnes, Roy M AU - Busund, Lill-Tove AU - Andersen, Sigve AU - Pezzella, Francesco PY - 2012 TI - Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer JF - Journal of Thoracic Disease; Vol 4, No 2 (April 30, 2012): Journal of Thoracic Disease Y2 - 2012 KW - N2 - Lung cancer is the no.1 cancer killer in both men and women. Non-small lung cancer (NSCLC) comprises about 80% of all lung cancers and approximately one third of these patients are diagnosed at stage I-IIIA where treatment intention is curative (1). Due to a significant risk of relapse after surgery, adjuvant platinum-based chemotherapy is today recommended in NSCLC stage II-III (2-4). Prospective randomised data failed to show significant survival benefit from adjuvant chemotherapy in stage IB (except in an unplanned subset analysis of patients with tumour size >4 cm) and even a detrimental effect was observed in stage IA (2). The fact that 30-40% of stage I patients relapse after surgical resection alone, indicates, however, that some of these patients might benefit from adjuvant treatment. UR - https://jtd.amegroups.org/article/view/333